Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening

• Published in: Scientific reports 2015-08, Vol.5 (1), p.13030-13030, Article 13030
• Main Authors: Otero-Estévez, Olalla, Chiara, Loretta De, Rodríguez-Girondo, Mar, Rodríguez-Berrocal, Francisco Javier, Cubiella, Joaquín, Castro, Inés, Hernández, Vicent, Martínez-Zorzano, Vicenta Soledad
• Format: Article
• Language: English
• Subjects: 692/308/1892; 692/53/2421; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Cohort Studies; Colon; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - enzymology; Colorectal Neoplasms - pathology; Enzyme-Linked Immunosorbent Assay; Feces; Female; Gelatinase B; Histology; Humanities and Social Sciences; Humans; Male; Matrix metalloproteinase; Matrix Metalloproteinase 9 - blood; Metalloproteinase; Middle Aged; multidisciplinary; Risk Factors; Science; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep13030

Matrix metalloproteinase-9 (MMP-9) is related to tumour development and progression in colorectal cancer (CRC) and its utility as biomarker has been suggested. The aim of our study was to measure serum MMP-9 in asymptomatic first-degree relatives of CRC patients and to analyse its diagnostic accuracy for the detection of advanced neoplasia (AN: advanced adenomas and CRC). Additionally, we compared its diagnostic capability with the most used non-invasive faecal immunochemical test (FIT). Serum MMP-9 was quantified by ELISA in 516 asymptomatic individuals that underwent a colonoscopy and a FIT. MMP-9 levels were significantly related to age and gender and therefore the concentration was corrected by these confounders. Corrected MMP-9 (cMMP-9) levels were higher in individuals with advanced adenomas (AA; p -value = 0.029) and AN ( p -value = 0.056) compared to individuals with no neoplasia. Moreover, elevated cMMP-9 concentration was associated with more severe characteristics of adenomas (number of lesions, size and histology). Nevertheless, the diagnostic accuracy of cMMP-9 was considerably lower than that of FIT for identifying AA (22.64% vs. 47.17% sensitivity, 90% specificity) or AN (19.30% vs. 52.63% sensitivity, 90% specificity). According to our results, serum MMP-9 cannot be considered of utility for the diagnosis of AN in CRC family-risk population screening.